| Literature DB >> 27460041 |
Berit Skjødeberg Toftegaard1,2,3, Flemming Bro4,5, Alina Zalounina Falborg4,6,5, Peter Vedsted4,6,5.
Abstract
BACKGROUND: Continuing medical education (CME) in earlier cancer diagnosis was launched in Denmark in 2012 as part of the Danish National Cancer Plan. The CME programme was introduced to improve the recognition among general practitioners (GPs) of symptoms suggestive of cancer and improve the selection of patients requiring urgent investigation. This study aims to explore the effect of CME on GP knowledge about cancer diagnosis, attitude towards own role in cancer detection, self-assessed readiness to investigate and cancer risk assessment of urgently referred patients.Entities:
Keywords: Attitude; Continuing medical education; Denmark; Diagnosis; Early detection of cancer; General practice; Knowledge; Readiness to investigate; Risk assessment
Mesh:
Year: 2016 PMID: 27460041 PMCID: PMC4962470 DOI: 10.1186/s12875-016-0496-x
Source DB: PubMed Journal: BMC Fam Pract ISSN: 1471-2296 Impact factor: 2.497
Characteristics of GPs. Age, gender and type of clinic are shown for all GPs in the Central Denmark Region (study base), GPs responding to the knowledge and attitude questionnaire, GPs completing the vignettes and GPs assessing risk of cancer for continuous patients. GPs are divided into the CME-participating GPs and the reference GPs
| GP characteristics | ||||
|---|---|---|---|---|
|
| Mean age Years (95 % CI) | Proportion of males % (95 % CI) | Proportion of solo GPs % (95 % CI) | |
| Study base | ||||
| Total | 831 (100) | 52.3 (51.7; 52.8) | 54.3 (50.9; 57.7) | 24.1 (21.2; 27.0) |
| Reference GPs | 634 (76.3) | 52.4 (51.7; 53.0) | 56.5 (52.6; 60.3) | 26.0 (22.6; 29.4) |
| CME-participating GPs | 197 (23.7) | 51.9 (50.8; 53.0) | 47.2 (40.2; 54.2) | 17.8 (12.4; 23.2) |
| GPs that completed knowledge and attitudes items | ||||
| Reference GPs | 121 (19.1) | 49.8 (48.3; 51.4) | 57.9 (48.9; 66.8) | 24.0 (16.3; 31.7) |
| CME-participating GPs | 81 (41.1) | 50.7 (48.8; 52.5) | 46.9 (35.8; 58.0) | 18.5 (9.9; 27.2) |
| GPs that completed vignettes | ||||
| Reference GPs | 116 (18.3) | 49.9 (48.4; 51.5) | 58.6 (49.5; 67.7) | 23.3 (15.5; 31.1) |
| CME-participating GPs | 80 (40.6) | 50.5 (48.7; 52.4) | 47.5 (36.3; 58.7) | 18.8 (10.0; 27.5) |
| GPs that assessed risk of cancer on urgently referred patients | ||||
| Reference GPs, before | 384 (60.6) | 51.6 (50.8; 52.4) | 52.6 (47.6; 57.6) | 26.8 (22.4; 31.3) |
| Reference GPs, after | 364 (57.4) | 51.7 (50.8; 52.6) | 53.6 (48.4; 58.7) | 22.3 (18.0; 26.5) |
| CME-participating GPs, before | 148 (75.1) | 51.6 (50.3; 52.9) | 45.9 (37.8; 54.1) | 17.6 (11.4; 23.8) |
| CME-participating GPs, after | 160 (81.2) | 51.9 (50.6; 53.1) | 46.9 (39.1; 54.7) | 15.6 (9.9; 21.3) |
Fig. 1Flowchart of the data collection. The left part illustrates the GP completion of questionnaires at baseline (1 month before the CME) and at follow-up (7 months after the CME). The right part illustrates the consecutive GP completion of one-page forms, including assessed risk of cancer in referred patients before and after the CME. 1GPs who completed a similar questionnaire in the ICBP study, module 3, September 2012. 2Proportion of study base. 3196 GPs completed both baseline and follow-up vignettes (116 reference GPs and 80 CME-participating GPs). 6 GPs were lost to follow-up due to a technical failure of the online survey system
The CME effect on GPs’ attitude towards own role in cancer detection. The proportion of GPs responding most appropriately is shown for each of the items; one month before (Before) and seven months after (After) the CME. GPs are divided into two groups: CME-participating group and reference group. An effect within a group is shown as a risk ratio (RR0 for the Reference group; RR1 for the CME-participating group). Comparisons between groups are shown as ratio of risk ratios (RR1/RR0)
| Reference group | CME-Participating group | Comparison between groups | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
| Most appropriate answers | Before | After | Before vs. after | Before | After | Before vs. after | RR1/RR0 (p*) | |
| % (n) | % (n) | RR0 (p*) | % (n) | % (n) | RR1 (p*) | |||
| If a patient referred by me to a cancer fast-track pathway turns out not to have cancer, it is overuse of health services. |
| 86.8 (105) | 84.3 (102) | 0.97 (0.419) | 81.5 (66) | 87.7 (71) | 1.08 (0.163) | 1.11 (0.241) |
| If a patient referred by me to a cancer fast-track pathway turns out not to have cancer, unnecessary strain has been placed on the patient. |
| 83.5 (101) | 79.3 (96) | 0.95 (0.221) | 75.3 (61) | 79.0 (64) | 1.05 (0.275) | 1.11 |
| The more of the patients referred by me to a cancer fast-track pathway turn out to have cancer, the better a doctor I am. |
| 57.9 (70) | 62.0 (75) | 1.07 (0.224) | 59.3 (48) | 79.0 (64) | 1.33 ( | 1.24 |
| I am a good doctor when I refer a patient to a cancer fast-track pathway based on a reasonable suspicion, as it quickly clarifies the suspicion. |
| 81.0 (98) | 81.8 (99) | 1.01 (0.823) | 86.4 (70) | 82.7 (67) | 0.96 (0.397) | 0.95 (0.537) |
| I am reluctant to order tests because of the risk of over-diagnosis. |
| 75.2 (91) | 75.2 (91) | 1.00 (1.000) | 71.6 (58) | 75.3 (61) | 1.05 (0.308) | 1.05 (0.314) |
| I find it hard to mention cancer suspicion to a patient with alarm symptoms of cancer. |
| 81.0 (98) | 83.5 (101) | 1.03 (0.402) | 74.1 (60) | 75.3 (61) | 1.02 (0.704) | 1.00 (0.813) |
| I feel well prepared to communicate with the cancer pathway coordinators. |
| 82.6 (100) | 78.5 (95) | 0.95 (0.224) | 79.0 (64) | 77.8 (63) | 0.98 (0.806) | 1.03 (0.697) |
Bold = significance level of p ≤ 0.05. *corrected for clustering at the study-step-level
The CME effect on GPs’ knowledge about cancer diagnosis. The proportion of GPs responding most appropriately (MAAA) is shown for each item; one month before (Before) and seven months after (After) the CME. GPs are divided into two groups: CME-participating group and reference group. An effect within a group is shown as a risk ratio (RR0 for the Reference group; RR1 for the CME-participating group). Comparisons between groups are shown as ratio of risk ratios (RR1/RR0)
| Reference group | CME Participating group | Comparison between groups | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
| MAAA | Before | After | Before vs. after | Before | After | Before vs. after | RR1/RR0 (p*) | |
| % (n) | % (n) | RR0 (p*) | % (n) | % (n) | RR1 (p*) | |||
| What is the likelihood that a 50-year-old patient having cancer at the time you choose to refer the patient to a cancer fast-track pathway? | 2–10 % | 29.8 (36) | 38.8 (47) | 1.31 | 23.5 (19) | 65.4 (53) | 2.79 | 2.13 |
| What is the likelihood that a patient aged 40 years or more, who is smoker, has lung cancer the second time s/he presents with haemoptysis in your practice? | 5–20 % | 33.1 (40) | 34.7 (42) | 1.05 (0.698) | 33.3 (27) | 58.0 (47) | 1.74 | 1.63 (0.160) |
| What is the likelihood that a patient aged 40 years or more has colorectal cancer the first time that s/he presents with unintended weight loss and new onset of constipation in your practice? | 2–6 % | 8.3 (10) | 9.9 (12) | 1.19 | 6.2 (5) | 28.4 (23) | 4.6 | 3.83 (0.055) |
| What is the likelihood that a lung cancer cannot be detected on a chest x-ray at the time of diagnosis? | ≥15 % | 81.8 (99) | 86.0 (104) | 1.05 (0.741) | 76.5 (62) | 81.5 (66) | 1.06 (0.243) | 1.07 (0.309) |
| What is the proportion of patients with colorectal cancer who presented an alarm symptom as the first sign of the disease to his/her general practitioner? | ≤60 % | 81.8 (99) | 86.0 (104) | 1.05 (0.449) | 82.7 (67) | 90.1 (73) | 1.09 | 1.04 (0.614) |
| What is the proportion of patients with ovarian cancer who can be detected by a pelvic examination (palpation) in general practice at the time of diagnosis? | ≤41 % | 90.0 (110) | 94.2 (114) | 1.04 (0.078) | 85.2 (69) | 92.6 (75) | 1.09 | 1.05 (0.322) |
Bold = significance level of p ≤ 0.05. *corrected for clustering at the study-step-level
The CME effect on GPs’ self-assessed readiness to investigate. The proportions of vignettes where the GP made a definitive action after first or second phase of the vignette; one month before (Before) and seven months after (After) the CME. GPs are divided into two groups: CME-participating group and reference group. An effect within a group is shown as an odds ratio (OR0 for the Reference group; OR1 for the CME-participating group). Comparisons between groups are shown as a ratio of odds ratios (OR1/OR0)
| Reference group | CME-participating group | Comparison between groups | |||||
|---|---|---|---|---|---|---|---|
| Before | After | Before vs. after | Before | After | Before vs. after | OR1/OR0* (p) | |
| % (n) | % (n) | OR0* (p) | % (n) | % (n) | OR1* (p) | ||
| Definitive action, at the end of first phase | 37.9 (88) | 40.1 (93) | 1.19 (0.444) | 36.9 (59) | 43.8 (70) | 1.70 (0.055) | 1.43 (0.316) |
| Definitive action, at the end of second phase | 77.2 (179) | 77.6 (180) | 1.04 (0.872) | 81.9 (131) | 88.8 (142) |
| 1.94 (0.119) |
Bold = significance level of p < 0.05. *adjusted for a study-step and type of vignette
The CME effect on GP cancer risk assessment when referring consecutive patients for urgent referral. The numbers of assessing GPs and assessed patients are shown together with the median (inter quartile interval (IQI)) and the mean (95 % CI) assessed risk of cancer before and after the CME. GPs are divided into two groups: CME-participating group and reference group. An effect within a group and comparisons between groups are shown as regression coefficients
| Reference group | CME-participating group | Comparison between groups | |||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| Before | After | Before vs. after | Before | After | Before vs. after | Regression coefficient* (p) | |
| Regression coefficient* (p) | Regression coefficient * (p) | ||||||
| GPs (n (%)) | 384 (60.6) | 364 (57.4) | 148 (75.1) | 160 (81.2) | |||
| Patients (n) | 1740 | 1276 | 610 | 838 | |||
| Median risk (% (IQI)) | 30 (10–50) | 30 (10–50) | 30 (10–50) | 15 (10–50) | |||
| Mean risk (% (95 % CI)) | 39.6 (38.1; 41.0) | 38.8 (37.1; 40.4) | −0.17 (0.063) | 39.0 (36.6; 41.4) | 27.4 (25.6; 29.3) | −1.10 | −0.93 |
Bold = significance level of p < 0.05. *adjusted for a study-step and patient’s gender and age, on square root scale